The 2nd AACR-IASLC Joint Conference on the Molecular Origins of Lung Cancer: Pro

描述（由申请人提供）：美国癌症研究协会（AACR）和国际肺癌研究协会（IASLC）正在联合组织第二次会议，主题是肺癌的分子起源：个性化预防和治疗的前景，以跟进2010年成功的会议。第二次会议将于2012年1月8日至11日在加州圣地亚哥万豪酒店举行，重点关注肺癌研究的分子和转化方面。肺癌仍然是美国最常见的癌症死亡原因。美国癌症协会估计，2010年有222,520例肺癌新病例（自2009年以来有所增加），158,080人死亡。过去15年的研究已经深入了解了不同类型非小细胞肺癌（NSCLC）的分子细微差别。在过去，用细胞毒性化疗药物靶向所有NSCLC的方法，一种“一刀切”的方法，提供了一个小的可测量的益处，但通常反应率低于20%2。最近，常见的非小细胞肺癌分子亚型被发现，允许更有针对性和基于亚型的治疗选择。NSCLC中研究最多的遗传变异是编码EGFR基因的突变。与没有EGFR突变的患者相比，有这种突变的患者对EGFR酪氨酸激酶抑制剂（如吉非替尼或厄洛替尼）有更好的应答率。同样在2010年，具有ALK融合的NSCLC分子亚型作为一种临床相关且可治疗的致癌突变出现在前沿。ALK融合亚型NSCLC对不同药物的反应与EGFR突变的病变不同（~57%对克里唑替尼的反应率），强调需要了解个体的肿瘤基因型以获得最佳治疗。需要多学科关注的肺癌研究领域的新进展有：赋予治疗耐药性的基因突变，肺癌的其他分子亚型，以及2010年11月NCI国家肺部筛查试验结果中报告的早期检测筛查的可能性。本次会议将汇集来自肺癌研究基础、临床和转化学科的300多名研究人员，并为他们提供一个讨论最新进展、检验新假设和建立新合作的场所。在我们过去成功的会议上，演讲者还将讨论化学预防的分子机制、早期检测、癌症干细胞、表观遗传学、新疗法、临床试验结果和许多其他主题。这次会议不仅是AACR和IASLC这两个致力于癌症研究的组织的一次动态合作，而且也是多种类型的科学家和倡导者的一次动态合作，这些科学家和倡导者需要对这种疾病进行全面的研究和治疗。

DESCRIPTION (provided by applicant): The American Association for Cancer Research (AACR) and the International Association for the Study of Lung Cancer (IASLC) are jointly organizing a second conference on the Molecular Origins of Lung Cancer: Prospects for Personalized Prevention and Therapy to follow up on the successful 2010 conference. This second conference will take place January 8-11, 2012 at the San Diego Marriott Hotel & Marina in San Diego, CA and will focus on the molecular and translational aspects of lung cancer research. Lung cancer remains the most common cause of cancer death in the United States. The American Cancer Society estimates there were 222,520 new cases of lung cancer in 2010 (an increase since 2009) with 158,080 deaths1. The last 15 years of research have provided insight into the molecular nuances that stratify different types of non-small-cell lung cancer (NSCLC). In the past an approach to target all NSCLC with cytotoxic chemotherapeutic agents, a "one size fits all approach," provided a small measureable benefit but often with response rates of less than 20%2. Most recently, common molecular subtypes of NSCLC have been found, allowing for more targeted and subtype-based treatment selection. The most studied genetic variant in NSCLC is mutation in the gene encoding EGFR. Patients with this mutation have a better response rate to EGFR tyrosine kinase inhibitors, such as gefitinib or erlotinib, than those without the EGFR mutation. Similarly in 2010, the molecular subtype of NSCLC with ALK fusions emerged to the forefront as a clinically relevant and treatable oncogenic mutation. The ALK fusion subtype of NSCLC responds to a different drug than those lesions with an EGFR mutation (~57% response rate to crizotinib), highlighting the need to understand an individual's tumor genotype for optimal treatment. Emerging advances in the field of lung cancer research that require multi-disciplinary attention are: genetic mutations that confer resistance to treatment, the other molecular sub-types of lung cancer, and the possibility of screening for early detection reported in the results of the November 2010 NCI National Lung Screening Trial. This conference will bring together over 300 investigators from the basic, clinical, and translational disciplines of lung cancer research and provide them with a venue to discuss their recent advances, test new hypotheses, and establish new collaborations. As in our past successful conference, presenters will also discuss molecular mechanisms of chemoprevention, early detection, cancer stem cells, epigenetics, novel therapeutics, clinical trial results, and many other topics. This conference is not only a dynamic collaboration of the AACR and the IASLC, two organizations committed to the study of cancer, but also a dynamic collaboration of the many types of scientists and advocates that are needed for the well-rounded study and treatment of this disease. PUBLIC HEALTH RELEVANCE: Lung cancer remains the most common cause of cancer death in the United States and accounts for 29% and 26% of cancer-related deaths in men and women, respectively. The American Cancer Society estimates there were 222,520 new cases of lung cancer in 2010, accounting for ~14-15% of all new cases of cancer diagnosed (an increase since 2009)1. Given the complex underlying genetic alterations in tumors and the complication of contributing environmental factors, it is critical to gain a better understanding of the disease from the view of patient advocates, physicians, basic, translational, and clinical scientists. This forum, provided by the collaboration of AACR and IASLC, will be critical for developing new ways of diagnosing, studying, and treating lung cancer.